Book ID: CBB223408454

The Japanese Pharmaceutical Industry: Its Evolution and Current Challenges (2011)

unapi

Umemura, Maki (Author)


Routledge


Publication Date: 2011
Physical Details: 208
Language: English

This book explores why Japan, despite being a world leader in many high technology industries such as automobiles and consumer electronics, is only a minor player in the global pharmaceutical industry. Japan provides a huge market for pharmaceuticals as the second largest consumer of prescription drugs after the United States, and is a massive importer of prescription drugs, relying on discoveries made elsewhere. This book charts the development of the industry, from the devastation resulting from the Second World War to its performance in the present day. Focusing in particular on antibiotics and anticancer drugs, the book analyses factors that have prevented Japan from leading the rapid advances in science and technology that have occurred globally over recent decades. Looking at the pharmaceutical industry, the book argues that the Japanese government’s research and development policies were not sufficiently incentivising. It also shows how the nature of capitalism in Japan - which featured close relations between government and industry as well as between and within firms - was appropriate for nurturing industrial development in the immediate post-war decades, but became much less effective in later years.

...More
Reviewed By

Review Julia S. Yongue (2019) Review of "The Japanese Pharmaceutical Industry: Its Evolution and Current Challenges". Pharmacy in History (pp. 175-176). unapi

Citation URI
https://data.isiscb.org/isis/citation/CBB223408454/

Similar Citations

Article Alessandro Demichelis; (2018)
Understanding vaccine hesitancy: Cognitive biases and the role of trust (/isis/citation/CBB568141355/)

Book Greene, Jeremy A.; Watkins, Elizabeth Siegel; (2012)
Prescribed: Writing, Filling, Using, and Abusing the Prescription in Modern America (/isis/citation/CBB001214574/)

Book Anthony Ryan Hatch; (2019)
Silent Cells: The Secret Drugging of Captive America (/isis/citation/CBB955008011/)

Book William Rosen; (2017)
Miracle Cure: The Creation of Antibiotics and the Birth of Modern Medicine (/isis/citation/CBB729311593/)

Book Nancy D. Campbell; (2020)
OD: Naloxone and the Politics of Overdose (/isis/citation/CBB601007525/)

Article Ferdinando Marinelli; (2019)
Ancora sulla pubblicità delle ditte farmaceutiche (/isis/citation/CBB265222432/)

Article Christoph Schimkowsky; (2022)
Anxious Mobilities: A Visual Inquiry into Pandemic Disruptions of Urban Railway Mobilities in Tokyo (/isis/citation/CBB460306619/)

Article Giulia Bovone; (2019)
L’Arsenico: da strumento di morte ad antitumorale (XIX – XX - XXI secolo) (/isis/citation/CBB158105733/)

Article María González-Moreno; Cristian Saborido; David Teira; (2015)
Disease-mongering through clinical trials (/isis/citation/CBB362630000/)

Thesis Quinn, Roswell; (2009)
Broader Spectrum: A History of Antibiotic R&D (/isis/citation/CBB001560664/)

Multimedia Object Zoë Bossiere; Sarah Fawn Montgomery; (2020)
Sarah Fawn Montgomery, “Quite Mad: An American Pharma Memoir” (Mad Creek Books, 2018) (/isis/citation/CBB148363336/)

Article Sonia Muzzarelli; (2020)
La formazione del patrimonio storico-artistico dell’Ausl della Romagna (/isis/citation/CBB385779940/)

Article Tsukahara, Togo; (March 2019)
Essay: Legacies and Networking: Japanese STS in Transformation (/isis/citation/CBB361317352/)

Article Suzuki, Akihito; Takabayashi, Akinobu; (March 2019)
Life, Science, and Power in History and Philosophy (/isis/citation/CBB780402741/)

Authors & Contributors
Bovone, Giulia
Montgomery, Sarah Fawn
Yoichiro, Murakami
Muzzarelli, Sonia
Marinelli, Ferdinando
Christoph Schimkowsky
Concepts
Pharmacy
Pharmaceutical industry
Medicine and society
Technoscience; science and technology studies
Medicine
Antibiotics
Time Periods
20th century
21st century
20th century, late
19th century
Early modern
Medieval
Places
United States
Japan
Great Britain
Spain
Italy
New Mexico (U.S.)
Institutions
Pfizer, Inc.
Comments

Be the first to comment!

{{ comment.created_by.username }} on {{ comment.created_on | date:'medium' }}

Log in or register to comment